Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals
Simone I. Richardson, Vimbai Sharon Madzorera, Holly Spencer, et al.
Cell Host & Microbe (2022) Vol. 30, Iss. 6, pp. 880-886.e4
Open Access | Times Cited: 105

Showing 76-100 of 105 citing articles:

Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection
Thandeka Moyo-Gwete, Simone I. Richardson, Roanne Keeton, et al.
PLoS Pathogens (2023) Vol. 19, Iss. 11, pp. e1011772-e1011772
Open Access | Times Cited: 3
Post-vaccination Omicron infections induce broader immunity across antigenic space than prototype mRNA COVID-19 booster vaccination or primary infection
Wei Wang, Sabrina Lusvarghi, Rahul Subramanian, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 5
Rapidly shifting immunologic landscape and severity of SARS-CoV-2 in the Omicron era in South Africa
Kaiyuan Sun, Stefano Tempia, Jackie Kleynhans, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 5
Booster vaccination with Ad26.COV2.S or an Omicron-adapted vaccine in pre-immune hamsters protects against Omicron BA.2
Maarten Swart, Joan van der Lubbe, Sonja Schmit-Tillemans, et al.
npj Vaccines (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 2
Serum concentration of antigen-specific IgG can substantially bias interpretation of antibody-dependent phagocytosis assay readout
Russell St. Germain, Emily L. Bossard, Lawrence Corey, et al.
iScience (2023) Vol. 26, Iss. 9, pp. 107527-107527
Open Access | Times Cited: 2
Extensive neutralization against SARS-CoV-2 variants elicited by Omicron-specific subunit vaccine as a heterologous booster
Pai Peng, Chengqian Feng, Jie Hu, et al.
iScience (2022) Vol. 25, Iss. 11, pp. 105465-105465
Open Access | Times Cited: 4
An omicron-specific neutralizing antibody test predicts neutralizing activity against XBB 1.5
Stephen A. Varvel, Marzena Galdzicka, Stephanie Nystrom, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Comparing Neutralizing Antibody Activity Over Time Between Naive and Convalesced COVID-19 Vaccinated Individuals
Lisette de Pillis, Rebecca Caffrey, Ge Che, et al.
Research Square (Research Square) (2024)
Open Access
Longitudinal Analysis of Neutralizing Antibodies Against SARS-CoV-1 and Different SARS-CoV-2 Strains in Breakthrough and Unvaccinated Covid-19 Patients in Thailand
Prapassorn Poolchanuan, Vichapon Tiacharoen, Adul Dulsuk, et al.
(2024)
Closed Access
First SARS-CoV-2 Omicron infection as an effective immune booster among mRNA vaccinated individuals: final results from the first phase of the PRIBIVAC randomised clinical trial
Xuan Ying Poh, I. Russel Lee, Chee Wah Tan, et al.
EBioMedicine (2024) Vol. 107, pp. 105275-105275
Open Access
Understanding the landscape of the SARS‐CoV‐2‐specific T cells post‐omicron surge
Akshay Binayke, Aymaan Zaheer, Siddhesh Vishwakarma, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 8
Closed Access
Assessing exit screening of SARS-CoV-2 in Japan: an analysis of the airport screening data of passengers from the United Kingdom, 2020–2022
Shi-Qi Liu, Asami Anzai, Hiroshi Nishiura
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access
SpiN-Tec: A T cell-based recombinant vaccine that is safe, immunogenic, and shows high efficacy in experimental models challenged with SARS-CoV-2 variants of concern
Natália Satchiko Hojo-Souza, Julia Castro, Graziella Gomes Rivelli, et al.
Vaccine (2024) Vol. 42, Iss. 26, pp. 126394-126394
Open Access
Mechanisms and Implications of IgG4 Responses to SARS-CoV-2 and Other Repeatedly Administered Vaccines
Anthony M. Marchese, Louis Fries, Hadi Beyhaghi, et al.
Journal of Infection (2024), pp. 106317-106317
Open Access
Omicron infection induces low-level, narrow-range SARS-CoV-2 neutralizing activity
Priscilla Turelli, María‐Eugenia Zaballa, Charlène Raclot, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 3
Shared N417-dependent epitope on the SARS-CoV-2 Omicron, Beta and Delta-plus variants
Thandeka Moyo-Gwete, Mashudu Madzivhandila, Nonhlanhla N. Mkhize, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 3
Omicron Infection Induces Low-Level, Narrow-Range SARS-CoV-2 Neutralizing Activity
Priscilla Turelli, María‐Eugenia Zaballa, Charlène Raclot, et al.
SSRN Electronic Journal (2022)
Open Access | Times Cited: 3
Fc effector activity and neutralization against SARS-CoV-2 BA.4 is compromised in convalescent sera, regardless of the infecting variant
Simone I. Richardson, Prudence Kgagudi, Nelia P. Manamela, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 3
Unpredicted protective function of Fc-mediated inhibitory antibodies for HIV and SARS-CoV-2 vaccines
Liyun Lin, Pierre Gantner, Shuang Li, et al.
The Journal of Infectious Diseases (2024)
Open Access
Unraveling the impact of SARS-CoV-2 mutations on immunity: insights from innate immune recognition to antibody and T cell responses
Rafael Bayarri‐Olmos, Adrian Sutta, Anne Rosbjerg, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Broad and potent neutralizing mAbs are elicited in vaccinated individuals following Delta/BA.1 breakthrough infection
Jeffrey Seow, Zayed A. Shalim, Carl Graham, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 1
Cross-protection and cross-neutralization capacity of ancestral and VOC-matched SARS-CoV-2 adenoviral vector-based vaccines
Sabrina E. Vinzón, María V. López, Eduardo G. Cafferata, et al.
npj Vaccines (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 1
Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants
Catherine Riou, Jinal N. Bhiman, Yashica Ganga, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 1
Building a Resilient Scientific Network for COVID-19 and Beyond
N. Esther Babady, Rachel M. Burckhardt, Florian Krammer, et al.
mBio (2022) Vol. 13, Iss. 5
Open Access | Times Cited: 2
Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters
María Rescigno, Chiara Agrati, Carlo Salvarani, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 1

Scroll to top